Replies to post #393966 on NorthWest Biotherapeutics Inc (NWBO)

[jondoeuk]

We know that ''temporary growth cessation in some mets,'' ''symptom improvement,'' ''tumour necrosis,'' and/or ''stable disease'' can occur during the natural course of tumour growth. So if you give a treatment and there are PRs and/or CRs, it is responsible for that.

Scans from two patients enrolled in ADAP's trial (now pivotal, with a BLA expected to be filed next year)



Also, follow-up data (the ORR is 39.4%, DCR is 84.8%, and there have been two CRs)


The company is working on a next-gen version. It has inducible IL-7 and IL-15, a dominant-negative TGF-B receptor and/or could overexpress PDE7A (which increases the ability to induce apoptosis in target cells as well as makes the TCR-T cells more resistant to the negative effects of forskolin, adenosine and PGE2). Personally, I would have liked them to go further and added a CD8a co-receptor into CD4+ T-cells and continue to build on the ex vivo expansion https://s3.amazonaws.com/content.stockpr.com/adaptimmune/files/pages/adaptimmune/db/212/content/Anderson+et+al+-+MAGE-A4+Preclinical+poster+FINAL.pdf https://d1io3yog0oux5.cloudfront.net/adaptimmune/files/pages/adaptimmune/db/329/description/Jillian+Rogers+-+DP005-20++SITC+2020+AKTi+eposter+CM07+copy.pdf

[ATLnsider]

Well said flipper44